In addition to the two coronavirus vaccines that have already been registered by the Russian Federation, another twenty-four COVID-19 vaccine candidates were reported by Interfax to be in various stages of development.
Inna Kulikova, the director of the Russian Health Ministry's Department of Emergency Medical Care and Health Risk Management, stated at the Medicine and Quality 2020 conference held on December 8, 2020, "The Health Ministry of the Russian Federation registered the Gam-Covid-Vac (Sputnik V) vaccine on August 11, 2020, and the EpiVacCorona vaccine two months later.”
Russia's COVID-19 Vaccine Development Plans Are Extensive
Russia’s COVID-19 Vaccine Development Plans Are Extensive
In addition to the two coronavirus vaccines that have already been registered by the Russian Federation, another twenty-four COVID-19 vaccine candidates were reported by Interfax to be in various stages of development.
Inna Kulikova, the director of the Russian Health Ministry's Department of Emergency Medical Care and Health Risk Management, stated at the Medicine and Quality 2020 conference held on December 8, 2020, "The Health Ministry of the Russian Federation registered the Gam-Covid-Vac (Sputnik V) vaccine on August 11, 2020, and the EpiVacCorona vaccine two months later.”
COVID-19 Vaccine Caution Issued by U.K. Officials
Warning issued after two people suffered adverse reactions on the first day of the U.K. mass vaccination program
U.S. Hospitals Running Out of ICU Beds for COVID-19 Patients
Hospitals serving more than 100 million Americans had less than 15 percent of intensive care beds still available as of last week
Canada Approves Pfizer COVID-19 Vaccine
Health Canada completed a full independent review of the data on the vaccine’s safety and effectiveness
Metformin Use May Reduce Mortality in Women With COVID-19
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
Hospitalization Up for Black Gynecologic Cancer Patients With COVID-19
Among patients with gynecologic cancer who died from COVID-19, 41.2 percent were Black
Innovative Peptide Study Evaluates Reduction in Liver Fat and Increased Weight Loss
A clinical-stage biopharmaceutical company announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801.
Altimmune, Inc. stated in a press release that ‘ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the USA.’
Positive In vitro Efficacy Data for Nasal Spray Protecting Against Coronavirus Infection
A Bermuda based clinical-stage company announced positive efficacy data from testing AM-301 nasal spray in vitro against a SARS-COV-2 coronavirus infection.
This study by Auris Medical Holding Ltd. reported up to 99.4 percent reduction of viral titer in human epithelial cell culture.